# A Study of ELX-02 in Patients With Alport Syndrome

> **NCT05448755** · PHASE2 · COMPLETED · sponsor: **Eloxx Pharmaceuticals, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Alport Syndrome

## Interventions

- **DRUG:** ELX-02

## Key facts

- **NCT ID:** NCT05448755
- **Lead sponsor:** Eloxx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05448755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05448755, "A Study of ELX-02 in Patients With Alport Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05448755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*